Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

MLA

Charles Zarnitsky, et al. “Evaluation of Two Strategies (Initial Methotrexate Monotherapy vs Its Combination with Adalimumab) in Management of Early Active Rheumatoid Arthritis: Data from the GUEPARD Trial.” Rheumatology, vol. 48, Sept. 2009, pp. 1429–34. EBSCOhost, https://doi.org/10.1093/rheumatology/kep261.

APA

Charles Zarnitsky, Olivier Meyer, Xavier Puéchal, Denis Mulleman, René Marc Flipo, Xavier Mariette, Thierry Schaeverbeke, Patrice Fardellone, Martin Soubrier, Jean Sibilia, Maxime Dougados, Bernarde Combe, & Francis Berenbaum. (2009). Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology, 48, 1429–1434. https://doi.org/10.1093/rheumatology/kep261

Chicago

Charles Zarnitsky, Olivier Meyer, Xavier Puéchal, Denis Mulleman, René Marc Flipo, Xavier Mariette, Thierry Schaeverbeke, et al. 2009. “Evaluation of Two Strategies (Initial Methotrexate Monotherapy vs Its Combination with Adalimumab) in Management of Early Active Rheumatoid Arthritis: Data from the GUEPARD Trial.” Rheumatology 48 (September): 1429–34. doi:10.1093/rheumatology/kep261.